ACADIA Pharmaceuticals, Inc. (ACAD)

ACADIA Pharmaceuticals, Inc. is a biopharmaceutical company focused on using its innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. All the company’s product candidates currently in the pipeline have been derived from discoveries made using its proprietary drug discovery platform.

The company’s portfolio of most advanced product candidates include three product candidates in clinical development and two product candidates in IND-track development. ACADIA’s pipeline addresses diseases that are currently not well served by available therapies and represent large potential commercial opportunities. Part of ACADIA’s core strategy is to selectively pursue strategic collaborations to advance and maximize the commercial potential of its pipeline.

As of June 30, 2009, the company had $70 million in total assets, $66.2 million of which was comprised of cash and investment securities available for sale. Current liabilities total $20.9 million and shareholder’s equity stands at $26.4 million. ACADIA anticipates that its cash, cash equivalents and investment securities will be greater than $40 million at December 31, 2009, and that its existing cash resources and payments from its collaborations will be sufficient to fund its operations at least into the first half of 2011.

Recent News